---
title: "Processing Speed Drives the Discriminative Value of a Smartphone Go/No-Go Task in Multiple Scleros"
id: "medrxiv-15-processing-speed-accounts-for-the-discriminative-power-of-a-smartphone-go-no-go"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-processing-speed-accounts-for-the-discriminative-power-of-a-smartphone-go-no-go"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.09.26362640v1?rss=1"
published_at: "2026-09-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Processing Speed Drives the Discriminative Value of a Smartphone Go/No-Go Task in Multiple Scleros
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-processing-speed-accounts-for-the-discriminative-power-of-a-smartphone-go-no-go
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.09.26362640v1?rss=1)
- **Published At:** 2026-09-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluated a smartphone-based equiprobable continuous vigilance **Go/No-Go** task integrated into the Neurological Functions Test Suite (NeuFun-TS) to measure cognition in multiple sclerosis (MS). - Researchers analyzed 3,270 quality-controlled trials from 303 participants, with primary analyses on 488 first-trial observations from 34 healthy donors (HD) and 213 MS participants. - Sixteen candidate metrics were screened from the raw event stream; 10 metrics were retained based on intrinsic psychometric properties. - Nine of the 10 retained outcomes significantly separated HD from MS; seven separated relapsing-remitting from progressive MS (all adjusted p < 0.05). - Discriminative power was driven almost exclusively by **response latency** (reaction time) rather than commission errors or inhibition metrics. - Composite multi-predictor scores did not outperform single reaction time metrics for diagnostic separation. - The Go/No-Go task demonstrated poor-to-moderate longitudinal test-retest reliability. - The task failed to provide incremental clinical value over existing NeuFun-TS modules: the randomized Symbol Digit Modalities Test (**rSDMT**) and the Motor Sequencing Test (**MST**). - Based on redundancy with simpler reaction time measures already on the platform and to reduce patient testing burden, the Go/No-Go module was removed from NeuFun-TS. - Ethical approvals and participant consent were obtained from the Institutional Review Board of the National Institutes of Health; data and code will be made available online upon journal acceptance.
## Clinical Analysis & Structured Key Points
Processing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis | medRxiv Skip to main content Processing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis View ORCID Profile Peter Kosa , View ORCID Profile Amir Moghadam Ahmadi , Marie Kanu , Yolanda Mejia , View ORCID Profile Emmanuel Mekasha , View ORCID Profile Caledonia Steltzner , View ORCID Profile Bibiana Bielekova doi: https://doi.org/10.64898/2026.09.09.26362640 Peter Kosa NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Peter Kosa Amir Moghadam Ahmadi NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Amir Moghadam Ahmadi Marie Kanu NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yolanda Mejia NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site Emmanuel Mekasha NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emmanuel Mekasha Caledonia Steltzner NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Caledonia Steltzner Bibiana Bielekova NIAID/NIH Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bibiana Bielekova For correspondence: bibi.bielekova{at}nih.gov Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Identifying and longitudinally measuring cognitive decline remains challenging because traditional assessments rely largely on episodic, in-person administration of analog scales by trained examiners. Smartphone technology provides a scalable alternative capable of extracting distinct digital biomarkers from continuous sensor and event streams. Following the integration of several cognitive modules into the self-administered Neurological Functions Test Suite (NeuFun-TS), this study evaluates the clinical utility and incremental validity of a final candidate module: an equiprobable (50/50) continuous vigilance Go/No-Go paradigm. Methods: We analyzed 3,270 quality-controlled trials from 303 participants, focusing primary analyses on 488 first-trial observations across 34 healthy donors (HD) and 213 multiple sclerosis (MS) participants. From the raw event stream, we screened 16 candidate metrics and retained 10 based on their intrinsic psychometric properties. Using these 10 metrics, we evaluated diagnostic group separation, test-retest reliability, correlations with clinical and magnetic resonance imaging (MRI) benchmarks, and incremental validity over existing digital modules: the randomized Symbol Digit Modalities Test (rSDMT) and the Motor Sequencing Test (MST), using paired observations. Results: Although nine of the 10 outcomes significantly separated HD from MS and seven separated relapsing-remitting from progressive MS subtypes (all adjusted p < 0.05), discriminative power was driven almost entirely by response latency rather than commission errors or inhibitory metrics. Multi-predictor composite scores offered no diagnostic advantage over reaction time alone. Furthermore, the Go/No-Go task demonstrated poor-to-moderate longitudinal test-retest reliability and failed to provide incremental clinical value over existing modules. Conclusion: Although the smartphone-based Go/No-Go task reflects processing speed impairment in MS, its discriminative capability is redundant with simpler reaction time metrics already implemented in the platform. Consequently, the Go/No-Go module was excluded from NeuFun-TS to minimize patient testing burden without compromising diagnostic sensitivity. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Institutional Review Board of the National Institutes of Health gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study will be available online upon acceptance of the manuscript by a peer-reviewed journal. https://github.com/Bielekova-Lab/neufun-go-no-go Funder Information Declared Intramural Research Program of the National Institutes of Health Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Back to top Previous Next Posted September 11, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Processing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Processing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis Peter Kosa , Amir Moghadam Ahmadi , Marie Kanu , Yolanda Mejia , Emmanuel Mekasha , Caledonia Steltzner , Bibiana Bielekova medRxiv 2026.09.09.26362640; doi: https://doi.org/10.64898/2026.09.09.26362640 Share This Article: Copy Citation Tools Processing Speed Accounts for the Discriminative Power of a Smartphone Go/No-Go Task in Multiple Sclerosis Peter Kosa , Amir Moghadam Ahmadi , Marie Kanu , Yolanda Mejia , Emmanuel Mekasha , Caledonia Steltzner , Bibiana Bielekova medRxiv 2026.09.09.26362640; doi: https://doi.org/10.64898/2026.09.09.26362640 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Neurology Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (898) Anesthesia (330) Cardiovascular Medicine (4802) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (647) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1625) Epidemiology (15918) Forensic Medicine (32) Gastroenterology (1200) Genetic and Genomic Medicine (7033) Geriatric Medicine (732) Health Economics (1064) Health Informatics (5031) Health Policy (1432) Health Systems and Quality Improvement (1757) Hematology (584) HIV/AIDS (1343) Infectious Diseases (except HIV/AIDS) (16278) Intensive Care and Critical Care Medicine (1170) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7254) Nursing (366) Nutrition (1080) Obstetrics and Gynecology (1239) Occupational and Environmental Health (1004) Oncology (3599) Ophthalmology (1048) Orthopedics (397) Otolaryngology (451) Pain Medicine (469) Palliative Medicine (139) Pathology (706) Pediatrics (1794) Pharmacology and Therapeutics (736) Primary Care Research (764) Psychiatry and Clinical Psychology (5881) Public and Global Health (9739) Radiology and Imaging (2409) Rehabilitation Medicine and Physical Therapy (1448) Respiratory Medicine (1246) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (775) Toxicology (107) Transplantation (304) Urology (290)
## Related Clinical Research

- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Carbon monoxide exposure may explain lower Parkinson's risk linked to smoking](https://medichelpline.com/clinical-feed/medical-news-today-0-why-smokers-may-have-a-lower-parkinson-s-risk-it-s-not-the-nicotine.md)
- [Novartis’ neuromuscular drug del-desiran fails Phase 3 HARBOR trial in DM1](https://medichelpline.com/clinical-feed/stat-news-6-stat-neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on.md)
- [Remote ambulation monitoring improves composite disability endpoints in MS and reduces trial sampl](https://medichelpline.com/clinical-feed/medrxiv-5-remote-ambulation-monitoring-enhances-composite-disability-measurement-in-ms-to.md)
- [Childhood Maltreatment, Poor Sleep, and Fear of Relapse in Multiple Sclerosis: A Clinical Summary](https://medichelpline.com/clinical-feed/medrxiv-1-exploring-the-negative-triad-of-childhood-maltreatment-fear-of-relapse-and-low.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.